Eikon Therapeutics, Inc. (NASDAQ:EIKN – Get Free Report) has received an average recommendation of “Hold” from the eight brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $25.00.
EIKN has been the subject of several analyst reports. Weiss Ratings raised Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Monday, August 3rd. Wedbush reduced their price target on Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating on the stock in a research report on Friday, August 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Eikon Therapeutics in a research note on Friday.
Check Out Our Latest Stock Analysis on EIKN
Eikon Therapeutics Stock Performance
Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.63) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.02). On average, analysts expect that Eikon Therapeutics will post -7.24 EPS for the current year.
Institutional Trading of Eikon Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new position in Eikon Therapeutics during the 2nd quarter worth approximately $624,000. Deutsche Bank AG bought a new stake in shares of Eikon Therapeutics in the 2nd quarter valued at $281,000. BlackRock Inc. increased its position in shares of Eikon Therapeutics by 29.0% during the second quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock worth $55,873,000 after buying an additional 962,046 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Eikon Therapeutics by 23.5% during the second quarter. The Manufacturers Life Insurance Company now owns 35,357 shares of the company’s stock worth $461,000 after buying an additional 6,734 shares during the period. Finally, Legal & General Group Plc bought a new position in Eikon Therapeutics during the second quarter worth $28,000.
About Eikon Therapeutics
We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.
Featured Articles
- Five stocks we like better than Eikon Therapeutics
- Deere Earnings: Has the Stock Outrun the Farm Cycle?
- BJ’s Wholesale Club Is Turning Stronger Fundamentals Into a Bullish Setup
- 3 Dividend Stocks Raising Their Payouts as Investors Search for Growth and Income
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
Receive News & Ratings for Eikon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eikon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
